CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics ...

Positive effects also demonstrated on reducing spleen size and life-threatening iron overload in the spleen, kidney and liver CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma, Inc., a ...

Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th In January, Acceleron reported that the PULSAR Phase 2 trial in patients ...

(Reuters) -Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring ...

Fusion startups have been on a fundraising tear lately, and a young startup, Acceleron Fusion, is joining the pack, having raised $15 million of a targeted $23.7 million round, according to an SEC ...

Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular ...

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs and heart. Merck will pay $180 per share in cash for ...

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its ...

Bristol Myers Squibb made Acceleron an offer that wasn't related to a buyout, but Acceleron turned it down. (Getty Images: Audtakorn Sutarmjam / EyeEm) Even though Acceleron sold itself to Merck for ...